Insulinoma screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(6 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Insulinoma}}
{{Insulinoma}}
{{CMG}}; {{AE}} {{PSD}}
{{CMG}}; {{AE}} {{ADS}}


==Overview==
==Overview==


There is insufficient evidence to recommend routine screening for [disease/malignancy].
There is insufficient evidence to recommend routine screening for insulinoma.
 
OR
 
According to the [guideline name], screening for [disease name] is not recommended.
 
OR
 
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
==Screening==
==Screening==


*There is insufficient evidence to recommend routine screening for [disease/malignancy].
*There is insufficient evidence to recommend routine screening for insulinoma.
OR
*According to the [guideline name], screening for [disease name] is not recommended.
OR
*According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
**[condition 1]
**[condition 2]
**[condition 3]


==References==
==References==
Line 30: Line 15:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
​​​​
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Gastroenterology]]
[[Category:Surgery]]

Latest revision as of 22:25, 29 July 2020